RenovoRx Receives Nasdaq Extension for Minimum Bid Price Compliance
RNXT sits 36% above its 52-week low of $0.701.
Summary
RenovoRx received an extension from Nasdaq until December 28, 2026, to meet the minimum $1.00 bid price requirement, continuing the delisting threat.
Key Events · Corporate Governance and Compliance · RNXT
-
Nasdaq Minimum Bid Price Deficiency
The company previously received a deficiency notice on December 31, 2025, for failing to meet Nasdaq's $1.00 minimum bid price requirement.
-
Compliance Period Extended
Nasdaq has granted an additional 180 calendar days, extending the compliance period until December 28, 2026.
-
Delisting Risk Remains
If the company fails to regain compliance by the new deadline, its common stock will be subject to delisting from Nasdaq, though an appeal process is available.
Analysis · RNXT · Life Sciences
RenovoRx has been granted an additional 180 days by Nasdaq to regain compliance with the $1.00 minimum bid price requirement. While this extension provides a temporary reprieve, the company remains at risk of delisting if it cannot maintain a closing bid price of at least $1.00 for 10 consecutive business days by the new deadline. This ongoing compliance issue poses a significant threat to the company's listing status and investor confidence.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNXT was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $43M. The 52-week trading range was $0.70 to $1.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.